Literature DB >> 27134260

Time Trends, Predictors, and Outcome of Emergency Department Use for Gout: A Nationwide US Study.

Jasvinder A Singh1, Shaohua Yu2.   

Abstract

OBJECTIVE: To assess gout-related emergency department (ED) use/charges and discharge disposition.
METHODS: We used the US National ED Sample (NEDS) data to examine the time trends in total ED visits and charges and ED-related hospitalizations with gout as the primary diagnosis. We assessed multivariable-adjusted predictors of ED charges and hospitalization for gout-related visits using the 2012 NEDS data.
RESULTS: There were 180,789, 201,044, and 205,152 ED visits in 2009, 2010, and 2012 with gout as the primary diagnosis, with total ED charges of $195 million, $239 million, and $287 million, respectively; these accounted for 0.14%-0.16% of all ED visits. Mean/median 2012 ED charges/visit were $1398/$956. Of all gout-related ED visits, 7.7% were admitted to the hospital in 2012. Mean/median length of hospital stay was 3.9/2.6 days and mean/median inpatient charge/admission with gout as the primary diagnosis was $22,066/$15,912 in 2012. In multivariable-adjusted analyses, these factors were associated with higher ED charges: older age, female sex, highest income quartile, being uninsured, metropolitan residence, Western United States hospital location, heart disease, renal failure, heart failure, hypertension (HTN), diabetes, osteoarthritis (OA), and chronic obstructive pulmonary disease (COPD). These factors were associated with higher odds of hospitalization: older age, Northeast location, metropolitan teaching hospital, higher income quartile, heart disease, renal failure, heart failure, hyperlipidemia, HTN, diabetes, COPD, and OA, whereas self-pay insurance status was associated with lower odds of hospitalization, following an ED visit for gout.
CONCLUSION: Absolute ED use and charges for gout increased over time, but relative use remained stable. Modifiable comorbidity factors associated with higher gout-related use should be targeted to reduce morbidity and healthcare use.

Entities:  

Keywords:  CHARGES; EMERGENCY ROOM; GOUT; HEALTHCARE USE; HOSPITALIZATION; INPATIENT USE

Mesh:

Year:  2016        PMID: 27134260      PMCID: PMC4970881          DOI: 10.3899/jrheum.151419

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  18 in total

Review 1.  Difficult-to-treat gouty arthritis: a disease warranting better management.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

2.  Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009.

Authors:  Philip C Robinson; Tony R Merriman; Peter Herbison; John Highton
Journal:  Rheumatology (Oxford)       Date:  2012-09-18       Impact factor: 7.580

3.  Gout medication treatment patterns and adherence to standards of care from a managed care perspective.

Authors:  Chaitanya A Sarawate; Kathleen K Brewer; Wenya Yang; Pankaj A Patel; H Ralph Schumacher; Kenneth G Saag; Alan W Bakst
Journal:  Mayo Clin Proc       Date:  2006-07       Impact factor: 7.616

4.  Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks.

Authors:  Joseph J Saseen; Neetu Agashivala; Richard Read Allen; Vahram Ghushchyan; Anthony M Yadao; Kavita V Nair
Journal:  Rheumatology (Oxford)       Date:  2012-07-23       Impact factor: 7.580

Review 5.  Treating to target: a strategy to cure gout.

Authors:  Fernando Perez-Ruiz
Journal:  Rheumatology (Oxford)       Date:  2009-05       Impact factor: 7.580

6.  Factors associated with recurrent hospital admissions for gout: a case-control study.

Authors:  Ingrid Hutton; Greg Gamble; Peter Gow; Nicola Dalbeth
Journal:  J Clin Rheumatol       Date:  2009-09       Impact factor: 3.517

7.  Incidence and treatment patterns in males presenting with lower urinary tract symptoms to the emergency department in the United States.

Authors:  Florian Roghmann; Khurshid R Ghani; Keith J Kowalczyk; Naeem Bhojani; Jesse D Sammon; Giorgio Gandaglia; Vincent Trudeau; Andreas Becker; Shyam Sukumar; Mani Menon; Kevin C Zorn; Pierre Karakiewicz; Maxine Sun; Joachim Noldus; Quoc-Dien Trinh
Journal:  J Urol       Date:  2013-06-11       Impact factor: 7.450

Review 8.  Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.

Authors:  R Micklewright; S Lane; W Linley; C McQuade; F Thompson; N Maskrey
Journal:  Aliment Pharmacol Ther       Date:  2003-02       Impact factor: 8.171

Review 9.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Authors:  Jasvinder A Singh; Kenneth G Saag; S Louis Bridges; Elie A Akl; Raveendhara R Bannuru; Matthew C Sullivan; Elizaveta Vaysbrot; Christine McNaughton; Mikala Osani; Robert H Shmerling; Jeffrey R Curtis; Daniel E Furst; Deborah Parks; Arthur Kavanaugh; James O'Dell; Charles King; Amye Leong; Eric L Matteson; John T Schousboe; Barbara Drevlow; Seth Ginsberg; James Grober; E William St Clair; Elizabeth Tindall; Amy S Miller; Timothy McAlindon
Journal:  Arthritis Rheumatol       Date:  2015-11-06       Impact factor: 10.995

10.  Gout-related health care utilization in US emergency departments, 2006 through 2008.

Authors:  Rohini Garg; Harlan R Sayles; Fang Yu; Kaleb Michaud; Jasvinder Singh; Kenneth G Saag; Ted R Mikuls
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-04       Impact factor: 4.794

View more
  9 in total

1.  Identification of Gout Flares in Chief Complaint Text Using Natural Language Processing.

Authors:  John D Osborne; James S Booth; Tobias O'Leary; Amy Mudano; Giovanna Rosas; Phillip J Foster; Kenneth G Saag; Maria I Danila
Journal:  AMIA Annu Symp Proc       Date:  2021-01-25

Review 2.  Epidemiology of osteoarthritis: literature update.

Authors:  Ernest R Vina; C Kent Kwoh
Journal:  Curr Opin Rheumatol       Date:  2018-03       Impact factor: 5.006

3.  Gout Flare Burden, Diagnosis, and Management: Navigating Care in Older Patients with Comorbidity.

Authors:  Mukund Kumar; Natalie Manley; Ted R Mikuls
Journal:  Drugs Aging       Date:  2021-06-09       Impact factor: 3.923

4.  Hospitalization Increases the Risk of Acute Arthritic Flares in Gout: A Population-based Study over 2 Decades.

Authors:  Nour Zleik; Mohanad M Elfishawi; Zoran Kvrgic; Clement J Michet; Cynthia S Crowson; Eric L Matteson; Tim Bongartz
Journal:  J Rheumatol       Date:  2018-07-01       Impact factor: 4.666

5.  Incident gout and chronic Kidney Disease: healthcare utilization and survival.

Authors:  Dena H Jaffe; Alyssa B Klein; Arriel Benis; Natalia M Flores; Hagit Gabay; Robert Morlock; Dana Y Teltsch; Jonathan Chapnick; Yair Molad; Shmuel M Giveon; Becca Feldman; Maya Leventer-Roberts
Journal:  BMC Rheumatol       Date:  2019-03-19

6.  Patterns of health care utilization of gout patients in Hawai'i-high rates of emergency department utilization as compared to rheumatoid arthritis.

Authors:  Victoria P Mak; Andrea M Siu; So Yung Choi; Hyeong Jun Ahn; Sian Yik Lim
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

7.  Comparison of Rates of Lower Extremity Amputation in Patients With and Without Gout in the US Department of Veterans Affairs Health System.

Authors:  Ted R Mikuls; Quint Soto; Alison Petro; Lindsay Helget; Punyasha Roul; Harlan Sayles; Brendan Cope; Tuhina Neogi; Brian LaMoreaux; James R O'Dell; Bryant R England
Journal:  JAMA Netw Open       Date:  2022-01-04

8.  Trends in hospital visits and healthcare costs of gout and seropositive rheumatoid arthritis in Korea from 2010 to 2017 using National Healthcare Claims.

Authors:  Kyeong Min Son; Ju-Ryoung Kim; Hang A Park; Hyun Ah Kim
Journal:  Korean J Intern Med       Date:  2021-10-26       Impact factor: 2.884

9.  Network Pharmacology-Based Prediction and Verification of the Potential Targets of Pinoresinol Diglucoside for OA Treatment.

Authors:  Hongkan Lou; Yang Zhang; Jianli Fang; Yong Jin
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-16       Impact factor: 2.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.